Encelle plans hydrogel matrix wound-healing trial:
This article was originally published in Clinica
Encelle has received a $100,000 grant from the US National Institutes of Health to evaluate its hydrogel matrix in wound-healing applications. The Raleigh, North Carolina company recently filed an investigational device exemption with the FDA and hopes to begin clinical trials of the product later this year. The matrix, an injectable biopolymer material, promotes the growth of new blood vessels and wound closing by mimicking processes in the body that occur during embryonic development. Encelle added that because the product may enable relatively scar-free healing, it could also be used in general and plastic surgery.